A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adolescents with obesity, liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks compared to 0.3% with placebo, with early treatment response predicting long-term effectiveness.39”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [39]
In the citing paper
“but modest reduction in main CVD factors over 56 weeks of treatment.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“In a key RCT, there were notable reductions in BMI SDS and higher percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112]”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“Approved by FDA/EMA from age 6.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“The liraglutidetreated group demonstrated a placebo-subtracted weight reduction of 5% (29).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [29]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Establishing a standard definition for child overweight and obesity worldwide: international survey
Cole, T. J. (2000) · BMJ · doi:10.1136/bmj.320.7244.1240 · Cited by 16,480
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Freedman, D. S., Mei, Z., Srinivasan, S. R., Berenson, G. S., & Dietz, W. H. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.042 · Cited by 1,562
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Research works printed but not linked: 1
- Frelut M-L De Filippo G. Drug treatment of child and adolescent obesity. In: Frelut M-L ed. ECOG eBook on child and adolescent obesity. 2015 (https://ebook.ecog-obesity.eu/chapter-treatment/drug-treatment-of-child-and-adolescent-obesity/).
Cited by
Items 201–300 of 720
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.017 · Cited by 28
A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity
Kim, A., Nguyen, J., Babaei, M., Kim, A., Geller, D. H., & Vidmar, A. P. (2023) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s383454 · Cited by 27
“However, prior to 2022, there were just three medications with FDA approval for the treatment of pediatric obesity: orlistat (approved for adolescents 12 years and older),(9,10) phentermine (approved for a 12-week course, in youth 16 years and older),(11) and liraglutide 3 mg daily (approved for adolescents 12 years a…”
BackgroundPAGE, L. C., & Freemark, M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00409-7 · Cited by 19
Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
Patel, D., & Smith, A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1947796 · Cited by 16
Lin, Y., Liao, F., Chao, H., Chen, A., Jeng, Y., Lin, C., Tiao, M., Yang, Y., Yeung, C., Chen, H., et al. (2025) · JGH Open · doi:10.1002/jgh3.70137 · Cited by 20
“Glucagon-like peptide-1 receptor (GLP-1) analogs show promise for treating pediatric MASLD, given their established efficacy and safety in managing pediatric type 2 diabetes mellitus and obesity [86].”
Krug, I., Dang, A. B., Portingale, J., Li, Y., & Won, Y. Q. (2025) · Nutrients · doi:10.3390/nu17233735 · Cited by 23
“Clinical trials show weight reduction efficacy in adolescents with higher weight or type 2 diabetes [115–117].”
Weight Management in Adolescents with Polycystic Ovary Syndrome
Moore, J. M., Waldrop, S., & Cree‐Green, M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00437-x · Cited by 23
Vermeiren, E., Bruyndonckx, L., Winter, B. Y. D., Verhulst, S. L., Eyck, A. V., & Hoorenbeeck, K. V. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.05.020 · Cited by 20
Gourgari, E., Huerta‐Saenz, L., Tonyushkina, K. N., Rosolowsky, E. T., & Guttmann‐Bauman, I. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13234 · Cited by 16
“A recent large RCT investigated the use of 3 mg/day of liraglutide versus placebo in adolescents with obesity between 12 and 17 years of age.(8) A total of 125 participants received liraglutide and 126 received placebo.”
BackgroundPharmacologic Weight Management in the Era of Adolescent Obesity
Raman, V. S., Gupta, A., Ashraf, A. P., Breidbart, E., Gourgari, E., Kamboj, M. K., Kohn, B., Krishnan, S., Lahoti, A., Matlock, K. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac418 · Cited by 15
Wang, J., Kang, J., Wu, C., Peng, T., Liao, L., Lee, M., Lee, J., & Chen, S. (2024) · Obesity Reviews · doi:10.1111/obr.13686 · Cited by 15
“37 Among the 15 studies included, 6 used liraglutide, 10,15,26,30,32,36 5 used exenatide, 27 – 29, 31 , 16.0 years, and among the studies that reported a minimum age, the youngest participant was 7 years old.”
BackgroundInfluentialSohn, M., Nam, S., Nauck, M. A., & Lim, S. K. (2024) · BMC Medicine · doi:10.1186/s12916-024-03483-z · Cited by 18
“Whereas GLP1RAs at higher doses were very effective for obesity management [38, 39].”
BackgroundBensignor, M. O., Kelly, A. S., & Arslanian, S. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043650 · Cited by 16
“The liraglutide group more commonly experienced hypoglycemia compared to placebo (26% versus 18%) with no severe hypoglycemia (49).”
BackgroundInfluentialSelf-citationForst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Chen, J., Zhang, Q., Wu, Q., Zhang, X., Xiang, Z., Zhu, S., Dai, T., & Si, Y.-X. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70151 · Cited by 17
Kumar, N., & D’Alessio, D. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac276 · Cited by 14
Adolescents with Type 2 Diabetes: Overcoming Barriers to Effective Weight Management
Salama, M., Biggs, B. K., Creo, A. L., Prissel, R., Nofal, A. A., & Kumar, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s365829 · Cited by 17
“Metformin and glucagon like peptide −1 (GLP-1) agonists are the medications approved by the Food and Drug Administration for adolescents with T2DM that do not present with ketosis or ketoacidosis at the time of diagnosis.(120,121) Insulin (basal or short acting) is recommended in those that present with ketosis/ketoac…”
BackgroundWeight Loss Interventions for Adults With Obesity-Related Asthma
Foer, D., Forno, E., Holguín, F., & Cahill, K. N. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.12.041 · Cited by 19
Zhao, L. Q., Li, W., Zhang, P., Wang, D., Yang, L., & Yuan, G. (2024) · Endocrine · doi:10.1007/s12020-024-03734-2 · Cited by 17
Bensignor, M. O., Arslanian, S. A., & Vajravelu, M. E. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001365 · Cited by 20
Self-citationUse of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity
Kavarian, P., MOSHER, T. E., & Haija, M. A. E. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001379 · Cited by 19
“7.14 to – 2.14) in an intention-to-treat analysis [19 ].”
InfluentialWahi, G., St‐Pierre, J., Johnston, B. C., Fitzpatrick‐Lewis, D., Usman, A., Sherifali, D., Merdad, R. A., Esmaeilinezhad, Z., Birken, C. S., Hamilton, J. K., et al. (2024) · Pediatric Obesity · doi:10.1111/ijpo.13169 · Cited by 19
Metformin Treatment of Pediatric Obesity
Raman, V. S., & Foster, C. M. (2021) · PEDIATRICS · doi:10.1542/peds.2020-044982 · Cited by 15
Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents
Apperley, L. J., Gait, L., Erlandson‐Parry, K., Laing, P., & Senniappan, S. (2021) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0714 · Cited by 17
Adipose-derived stem cells and obesity: The spear and shield relationship
Yang, H., Li, C., Li, Y., Tai, R., & Sun, C. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.09.004 · Cited by 18
Friesen, C. S., Hosey, C. M., Chan, S. S., Csanaky, I. L., Wagner, J. B., Sweeney, B. R., Friesen, A., Fraser, J. D., & Shakhnovich, V. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.663351 · Cited by 18
“Although therapeutic end-points for NAFLD were not included in this trial, greater than 5% reduction in BMI, previously associated with improvement in NAFLD (20), was achieved in almost half (43%) of liraglutidetreated participants, versus 19% of participants receiving lifestyle modification therapy alone (39).”
BackgroundCardiovascular Safety and Superiority of Anti-Obesity Medications
Alobaida, M., Alrumayh, A., Oguntade, A. S., Al-Amodi, F., & Bwalya, M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s311359 · Cited by 15
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
Zaitoon, H., Wauters, A. D., Rodríguez, L. M., & Lynch, J. L. (2025) · Children · doi:10.3390/children12111427 · Cited by 15
“%] mean weight loss, outperforming lifestyle intervention alone [21,24].”
Yu, X., Bian, X., Zhang, H., Yang, S., Cui, D., & Su, Z. (2023) · IUBMB Life · doi:10.1002/iub.2760 · Cited by 14
Gou, H., Zhai, Y., & Guo, J. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05186-8 · Cited by 15
“Three studies had larger sample sizes and longer durations, covering more than 50 participants with intervention durations over 50 weeks [20, 22, 24].”
BackgroundMethodInfluentialObesity treatment in adolescents and adults in the era of personalized medicine
Sundbom, M., Järvholm, K., Sjögren, L., Nowicka, P., & Lagerros, Y. T. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13816 · Cited by 17
“Adolescents randomized to placebo increased their weight by 2.2% during the same time [26].”
InfluentialCurrent Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review
Niechciał, E., Wais, P., Bajtek, J., & Kędzia, A. W. (2024) · Nutrients · doi:10.3390/nu16234084 · Cited by 26
Glucagon‐like peptide‐1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
Bensignor, M. O., Wolf, J. M., Rudser, K. D., Kelly, A. S., & Arslanian, S. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14681 · Cited by 12
“Therefore, GLP-1RAs were an attractive ‘off-label’ adjunct therapy in youth with T2D and obesity to reduce body weight and HbA1c prior to the FDA approval of liraglutide and exenatide ER.(19-21) As more GLP-1RAs become FDA approved, an area of additional research should be to evaluate how prescribing patterns change o…”
BackgroundSelf-citationProgress in pediatric obesity: new and advanced therapies
Cuda, S. E., & Censani, M. (2022) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001150 · Cited by 15
Anti-obesity weight loss medications: Short-term and long-term use
Jeong, D., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120825 · Cited by 21
Zhao, G., Zhang, Q., Wu, F., Yin, S., Xie, Y., & Liu, H. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2117152 · Cited by 16
Barbieri, E., Santoro, N., & Umano, G. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1062341 · Cited by 14
“However, despite evidence showing an effect of semaglutide (53)on NAFLD, this class of medications is not approved for NAFLD, but for obesity (54) and type 2 diabetes (55) in youth.”
BackgroundAla, M., & Eftekhar, S. P. (2023) · Obesity Reviews · doi:10.1111/obr.13563 · Cited by 15
“Although, there was a higher chance of weight gain after discontinuation of liraglutide.(163)”
BackgroundHasanzad, M., Sarhangi, N., Nikfar, S., Ostad, S. N., & Meybodi, H. R. A. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00619-9 · Cited by 16
Risk of developing chronic kidney disease in young-onset Type 2 diabetes in Korea
Lee, J., Lee, S., Yoon, K., Cho, J., Han, K., & Yang, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-36711-2 · Cited by 13
“Anti-diabetic agents, such as SGLT2 inhibitors or GLP1 receptor agonists, have been shown to delay the progression of CKD (microalbuminuria, GFR) 32–35 .”
BackgroundDoyle, W. N., Reinhart, N. M., Reddy, N. C., Diab, A.-R. F., Sujka, J. A., DuCoin, C. G., & Docimo, S. (2023) · Cureus · doi:10.7759/cureus.50905 · Cited by 13
Bensignor, M. O., Kelly, A. S., Kunin‐Batson, A., Fox, C. K., FREESE, R. L., Clark, J., Rudser, K. D., Bomberg, E. M., Ryder, J. R., & Gross, A. C. (2024) · Pediatric Obesity · doi:10.1111/ijpo.13105 · Cited by 18
“7,9,10 Predicting who will respond to a given intervention and prevent weight regain following initial BMI reduction represents an important step towards tailored obesity treatment with effective and long-term results whilst avoiding ineffective medication exposure.”
BackgroundSelf-citationThe “Burden” of Childhood Obesity on Bone Health: A Look at Prevention and Treatment
Farella, I., Chiarito, M., Vitale, R., D’Amato, G., & Faienza, M. F. (2025) · Nutrients · doi:10.3390/nu17030491 · Cited by 20
Giovanni, C. B. S., Sweeney, B. R., Skelton, J. A., Kelsey, M. M., & Kelly, A. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab276 · Cited by 13
Self-citationZu, P., Xu, S., Shi, C.-Y., Zhao, Y.-Q., Huang, Z., & Tao, F. (2022) · Journal of Public Health · doi:10.1093/pubmed/fdac015 · Cited by 13
Treating Obesity in Children and Adolescents with Special Healthcare Needs
Gillette, M. L. D., Killian, H. J., Fernández, C., & Sweeney, B. R. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00484-y · Cited by 12
Alshehri, A., AlFaris, N., Al Qahtani, A. M., Shams, M., & Yahia, M. (2023) · Clinical Obesity · doi:10.1111/cob.12594 · Cited by 11
Anker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Wu, H., Lu, Z., Chen, R., Cai, Q., Wang, M., Zhang, L., & Zhu, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1098032 · Cited by 15
“Notably, the gastrointestinal adverse events of liraglutide were as high as 60% to 80% in overweight adolescents without diabetes (14, 15).”
BackgroundRussell, S., Mytton, O. T., & Viner, R. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(23)00216-5 · Cited by 10
Stenlid, R., Cerenius, S. Y., Quan, W., Aydın, B. K., Manell, H., Chowdhury, A. I., Kristinsson, H., Ciba, I., Gjessing, E. S., Mörwald, K., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1293093 · Cited by 11
“Obesity is a chronic, relapsing disease, associated with numerous co-morbidities and complications (4).”
BackgroundResultInfluentialUpdate on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
Ahn, Y. J., Maya, J., & Singhal, V. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00566-z · Cited by 12
Cuda, S. E., Censani, M., O’Hara, V. M., Paisley, J., Kharofa, R. Y., Conroy, R., Sweeney, B. R., Fernández, C., Gillette, M. L. D., & Browne, N. T. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100113 · Cited by 13
“0.87 with placebo [62,109, 110].”
InfluentialDai, M., Dai, S., Gu, L., Xiang, Z., Xu, A., Lu, S., Yang, Y., & Zhou, C. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-1-5 · Cited by 13
Katole, N. T., Salankar, H. V., Khade, A. M., Kale, J. S., Bankar, N. J., Gosavi, P. A., Dudhe, B., Mankar, N., & Noman, O. (2024) · Cureus · doi:10.7759/cureus.66280 · Cited by 25
“Among the seven studies included, three used exenatide [15-17], three used liraglutide [18-20], and the remaining one used semaglutide [21] as intervention.”
BackgroundMethodResultInfluentialHe, Y., Song, W., Deng, Y., Lin, X., Gao, Z., & Ma, P. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112441 · Cited by 13
Liraglutide for management of adolescent obesity
Kelishadi, R. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0371-7 · Cited by 11
Grammatikopoulou, M. G., Gkouskou, K. K., Gkiouras, K., Bogdanos, D. P., Eliopoulos, A. G., & Goulis, D. G. (2022) · Current Nutrition Reports · doi:10.1007/s13668-022-00404-5 · Cited by 12
Modern strategies for the treatment of childhood obesity
Vasyukova, O. V., Okorokov, P. L., & Bezlepkina, O. B. (2022) · Problems of Endocrinology · doi:10.14341/probl13208 · Cited by 18
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Mainieri, F., Bella, S. L., Rinaldi, M., & Chiarelli, F. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05427-4 · Cited by 15
“Several studies have shown that adolescents with common obesity can achieve successful outcomes when treated with glucagon-like peptide 1 (GLP1) agonists [15].”
Jebeile, H., Danielsen, Y. S., Sumithran, P., Lorien, S. J., Jardine, I. R., Baur, L. A., & Lister, N. B. (2025) · Obesity Reviews · doi:10.1111/obr.70049 · Cited by 14
“One multicenter RCT tested liraglutide 3.0 mg daily ( n = 125) compared to placebo ( n = 126) in adolescents with obesity [46].”
InfluentialZhang, J., Xu, H., Lu, J., Dong, Y., & Feng, J. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117291 · Cited by 11
Factors affecting the use of herbal medicines for weight loss in overweight and obese adolescents
Yim, M. H., & Lee, B. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1166786 · Cited by 11
Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery
Anekwe, C. V., Knight, M. G., Seetharaman, S., Dutton, W. P., Chhabria, S. M., & Stanford, F. C. (2021) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-021-00358-7 · Cited by 11
Adolescent obesity treatments: news, views, and evidence
Cominato, L., Franco, R. R., & Damiani, D. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000393 · Cited by 16
“There were no differences in adverse events of suicidal ideation or behavior reported by patients with obesity treated with liraglutide or placebo (35,39).”
BackgroundInfluentialSleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats
Fang, J., Miller, P., & Grigson, P. S. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.11.012 · Cited by 13
Metabolic-Associated Fatty Liver Disease in Childhood and Adolescence
Vespoli, C., Iqbal, A. M., Kabbany, M. N., & Radhakrishnan, K. R. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.02.001 · Cited by 13
Zaitoon, H., Lubetzky, R., Amir, A. Z., Moran‐Lev, H., Sagi, L., Bach, M. Y., Borger, O., Chorna, E., Lebenthal, Y., & Brener, A. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02109-9 · Cited by 12
“GLP-1a for the treatment of obesity in adolescents had been introduced in 2020 [21], it was presented to the boy’s parents as a therapeutic option.”
BackgroundMedical Treatment of Obstructive Sleep Apnea in Children
Ergenekon, P., Gökdemir, Y., & Ersu, R. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155022 · Cited by 14
“5% of placebo group participants; a decrease in BMI of at least 10% was seen in 33% and 9% of participants, respectively [99].”
BackgroundTreatment of type 2 diabetes in children: what are the specific considerations?
Grøndahl, M. F. G., Johannesen, J., Kristensen, K., & Knop, F. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1954160 · Cited by 13
Liraglutide for Adolescents with Obesity
Anker, M. S., Butler, J., & Anker, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2023284 · Cited by 10
Mitra, A. T., Das, B., Sarraf, K. M., Ford‐Adams, M., Fehervari, M., & Ashrafian, H. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102462 · Cited by 14
Järvholm, K., Janson, A., Henfridsson, P., Neovius, M., Sjögren, L., & Olbers, T. (2024) · Scandinavian Journal of Surgery · doi:10.1177/14574969241297517 · Cited by 11
Parizad, R., Hatwal, J., Brar, A. S., Alizadeh, L., Goyal, M. K., Batta, A., & Mohan, B. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v15.i1.111030 · Cited by 9
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
Kohut, T. J., & Panganiban, J. A. (2021) · JPGN Reports · doi:10.1097/pg9.0000000000000141 · Cited by 9
“0 mg daily) has been FDA approved since 2014 for chronic weight management in adults with obesity and recently gained approval in 2020 for chronic weight management in adolescents with obesity (10, 13).”
Is polypharmacy the future for pharmacological management of obesity?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100322 · Cited by 12
“The obesity pandemic” in the COVID-19 pandemic – new treatment for an old problem
Fabin-Czepiel, K., Pieczyńska-Chapuła, K., & Deja, G. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.129342 · Cited by 11
Metabolic and Bariatric Surgery in Children: Current Practices and Outcomes
Shah, S. A., Khan, N. A., & Qureshi, F. (2024) · Current Obesity Reports · doi:10.1007/s13679-023-00540-1 · Cited by 9
Challenges and pitfalls of youth-onset type 2 diabetes
Sabolić, L. L. G., Marusic, S., & Berković, M. C. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.876 · Cited by 10
Nguyen, A., Smith, E., Hashemy, H., Agarwal, S. M., Hahn, M., Paterson, A. D., & Dash, S. (2024) · Clinical Obesity · doi:10.1111/cob.12676 · Cited by 11
“Increasingly, these medications are now being prescribed in younger patients 37,38 and are being evaluated in people with substance use disorder 39 – 41 and Parkinson's disease, 42 who may be at increased risk of suicide attempts.”
Mai, G., Fan, L., Li, M.-P., Zhang, P., Gan, C., Huang, Q., & Shentu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.610880 · Cited by 9
“Recently, liraglutide plus lifestyle therapy was found to significantly lower BMI standard-deviation score in adolescents with obesity (Kelly et al., 2020).”
BackgroundConcepcion, J. Q., Tucker, L.-Y. S., & Huang, K. (2021) · Obesity · doi:10.1002/oby.23207 · Cited by 9
“In December 2020, based on data from a randomized clinical trial involving 250 adolescents with obesity, the FDA approved the glucagonlike peptide 1 (GLP1) analogue liraglutide as a weight management therapy for patients aged 12 years and older (10).”
MethodGross, A. C., FREESE, R. L., Bensignor, M. O., Bomberg, E. M., Dengel, D. R., Fox, C. K., Rudser, K. D., Ryder, J. R., Bramante, C. T., Raatz, S. J., et al. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.1701 · Cited by 10
Self-citationVilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.019 · Cited by 8
Kochis, M. A., Bizimana, C., Zitsman, J. L., Pratt, J. S. A., & Griggs, C. L. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.05.045 · Cited by 8
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
Roberts, R. E., Markande, A., Kasaven, L. S., Chieveley-Williams, S., Faris, R., Bracewell‐Milnes, T., Thum, Y., Nicopoullos, J. D. M., & Jones, B. P. (2025) · Obesity Reviews · doi:10.1111/obr.70015 · Cited by 11
Tou, A. M., & Panganiban, J. A. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70242 · Cited by 11
Zhao, F., Zou, Z., Liu, Z., Wang, J., Wu, Y., Zhang, J., Liu, Q., Liang, W., Yao, J., Jiang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64892-z · Cited by 14
Jansson, A. K., Gómez‐Martín, M., Hedin, L. E., Clarke, E. D., Cross, V., Stanford, J., Taylor, R., Bogl, L. H., de Vlieger, N., Koochek, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70077 · Cited by 13
Peterson, A. L. H., Ashraf, A. P., Bachman, J., Hegele, R. A., Rashad, M., South, A. M., Tran, A. H., Zachariah, J. P. V., & Wong, J. P. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000195 · Cited by 8
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
Consensus on pharmacological treatment of obesity in Latin America
Cappelletti, A. M., Montero, A. V., Cercato, C., Ossman, J. J. D., Vasquez, P. E. F., García, J. E. G., Mancillas‐Adame, L. G., Manrique, H. A., Monterroso, F. D. M. R., Segarra, P., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13683 · Cited by 10
Efficacy of liraglutide in pediatric obesity: A review of clinical trial data
Agosta, M., Sofia, M., Pezzino, S., D’Amato, S., Litrico, G., Mazzone, C., Greca, G. L., & Latteri, S. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100545 · Cited by 10
Bomberg, E. M., Clark, J., Rudser, K. D., Gross, A. C., Kelly, A. S., & Fox, C. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1369270 · Cited by 8
“(29).”
BackgroundInfluentialSelf-citationToma, T., Miyakawa, N., Arakaki, Y., Watanabe, T., Nakahara, R., Ali, T. F. S., Biswas, T., Todaka, M., Kondo, T., Fujita, M., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06260-y · Cited by 10
“The glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide, developed in the 2000s, is attracting attention as a glucose-lowering medication; liraglutide also induces weight loss in individuals with BMI ≥30 kg/m 2 [23, 24].”
A recent update on childhood obesity: aetiology, treatment and complications
Hawton, K., Shirodkar, D., Siese, T., Hamilton-Shield, J. P., & Giri, D. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0316 · Cited by 17
Nonalcoholic Steatohepatitis in Children
Xanthakos, S. A. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.05.001 · Cited by 10
Metadata
- Authors
- Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); Novo Nordisk, Søborg, Denmark (P.A.); Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Plainsboro, NJ (P.M.H.); the Division of Pediatrics, Department of Clinical Science Intervention and Technology,...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-28
- Volume
- 382
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013213902
- Cited by
- 723
- References
- 34
- Citations by year
- 2026: 133 · 2025: 143 · 2024: 149 · 2023: 109 · 2022: 80 · 2021: 80 · 2020: 26
- FWCI
- 44.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, adolescent obesity, childhood obesity, weight management, GLP-1 receptor agonists, lifestyle therapy, body mass index, gastrointestinal adverse effects, drug discontinuation, long-term weight maintenance, drug efficacy
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adolescent, Blood Glucose, Child, Combined Modality Therapy, Double-Blind Method, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Injections, Subcutaneous, Male, Body Mass Index, Incretins, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.